Contraception in HIV-positive female adolescents

AIDS Research and Therapy

Volumn 8, Issue , 2011, Pages

  Kancheva Landolt, Nadia T ^a   Lakhonphon, Sudrak ^b   Ananworanich, Jintanat ^a,b,c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b SEARCH   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CONTRACEPTIVE AGENT; EFAVIRENZ; ETHINYLESTRADIOL; ETRAVIRINE; GESTAGEN; LEVONORGESTREL; LOPINAVIR PLUS RITONAVIR; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; RITONAVIR; SAQUINAVIR; TENOFOVIR DISOPROXIL;

ADOLESCENT; BONE METABOLISM; CONDOM; CONTRACEPTION; DRUG ACTIVITY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE;

EID: 79957651401     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-8-19     Document Type: Review

References (71)

1. UNAIDS Report on the global AIDS epidemic. Geneva, UNAIDS. 2009, UNAIDS., http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf
2. Ezeanolue EE, Wodi AP, Patel R, Dieudonne A, Oleske JM. Sexual behaviors and procreational intentions of adolescents and young adults with perinatally acquired human immunodeficiency virus infection: experience of an urban tertiary center. J Adolesc Health 2006, 38(6):719-25. 10.1016/j.jadohealth.2005.06.015, 16730601.
3. Dallao M. HIV-Infected Youth. , http://www.fhi.org/NR/rdonlyres/eew5mfvd6vkink4vw7dwdxzrfz6nareomrt6ah4ufcqkzftpbi3bwbsl6p7p3mbqaw6uqi5lp7vjxc/YL29e.pdf
4. Levin L, Henry-Reid L, Murphy DA, Peralta L, Sarr M, Ma Y, Rogers AS, . Adolescent Medicine HIV/AIDS Research Network Incident pregnancy rates in HIV infected and HIV uninfected at-risk adolescents. J Adolesc Health 2001, 29(3 Suppl):101-8. Adolescent Medicine HIV/AIDS Research Network.
5. Koenig LJ, Pals SL, Chandwani S, Hodge K, Abramowitz S, Barnes W, D'Angelo L. Sexual transmission risk behavior of adolescents With HIV acquired perinatally or through risky behaviors. J Acquir Immune Defic Syndr 2010, 55(3):380-90. 10.1097/QAI.0b013e3181f0ccb6, 20802343.
6. Rongkavilit C, Naar-King S, Chuenyam T, Wang B, Wright K, Phanuphak P. Health Risk Behaviors among HIV-Infected Youth in Bangkok, Thailand. J Adolesc Health 2007, 40(4):358.e1-358.e8.
7. Cruz ML, Cardoso CA, João EC, Gomes IM, Abreu TF, Oliveira RH, Machado ES, Dias IS, Rubini NM, Succi RM. Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants. AIDS 2010, 24(17):2727-2731. 10.1097/QAD.0b013e32833e50d4, 20827164.
8. Schutt-Aine J, Maddaleno M. Sexual health and development of adolescents and youth in the Americas: program and policy implications. 2003, PAHO, Washington, DC., http://www.paho.org/English/HPP/HPF/ADOL/SRH.pdf
9. Kancheva Landolt N, Phanuphak N, Chaithongwongwatthana S, Ananworanich J. Sexual life and contraception in people living with HIV. Asian Biomedicine 2010, 4(5):691-701.
10. British HIV Association UK Guidelines for the management of sexual and reproductive health of people living with HIV infection. 2008, British HIV Association., http://www.bhiva.org
11. Patterson TL, Mausbach B, Lozada R, Staines-Orozco H, Semple SJ. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Am J Public Health 2008, 98(11):2051-2057. 10.2105/AJPH.2007.130096, 2633868,2633868, 18799768.
12. Hiltabiddle SJ. Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. J Obstet Gynecol Neonatal Nurs 1996, 25(1):61-6. 10.1111/j.1552-6909.1996.tb02514.x, 8627404.
13. Wilson TE, Koenig LJ, Walter E, Fernandez I, Ethier K. Perinatal Guidelines Evaluation Project. Dual contraceptive method use for pregnancy and disease prevention among HIV-infected and HIV-uninfected women: the importance of an event-level focus for promoting safer sexual behaviors. Sex Transm Dis 2003, 30(11):809-12. 10.1097/01.OLQ.0000086617.41012.14, 14603086.
14. Ngubane N, Patel D, Newell ML, Coovadia HM, Rollins N, Coutsoudis A. Messages about dual contraception in areas of high HIV prevalence are not heeded. S Afr Med J 2008, 98(3):209-12.
15. Berer M. Dual protection: more needed than practised or understood. Reprod Health Matters 2006, 14(28):162-70. 10.1016/S0968-8080(06)28262-4, 17101435.
16. Pazol K, Kramer MR, Hogue CJ. Condoms for dual protection: patterns of use with highly effective contraceptive methods. Public Health Rep 2010, 125(2):208-17. 2821848, 20297747.
17. Mallet J, Kalambi V. Coerced and forced sterilization of HIV-positive women in Namibia. HIV AIDS Policy Law Re 2008, 13(2-3):77-8.
18. Curtis KM, Mohllajee AP, Peterson HB. Regret following female sterilization at a young age: a systematic review. Contraception 2006, 73(2):205-210. 10.1016/j.contraception.2005.08.006, 16413851.
19. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, Matongo I, Vermund SH, Mwanahamuntu M, Stringer JS. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007, 197(2):144.e1-8.
20. Doll H, Vessey M, Painter R. Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. BJOG 2001, 108(3):304-14.
21. Zhang J, Feldblum PJ, Chi IC, Farr MG. Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception 1992, 46(5):427-33. 10.1016/0010-7824(92)90146-K, 1458889.
22. Patchen L, Berggren EK. Use of the Copper T380A Intrauterine Device by Adolescent Mothers: Continuation and Method Failure. J Pediatr Adolesc Gynecol 2011, 24(2):71-3. 10.1016/j.jpag.2010.07.010, 20869276.
23. Gold MA, Johnson LM. Intrauterine devices and adolescents. Curr Opin Obstet Gynecol 2008, 20(5):464-9. 10.1097/GCO.0b013e32830a98f8, 18797269.
24. WHO Medical Eligibility Criteria for Contraceptive Use. Geneva, WHO. 2004, WHO., http://www.who.int/reproductivehealth/publications/family_planning/9241562668index/en/index.html
25. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS 2009, 23(suppl 1):S55-S67. 10.1097/01.aids.0000363778.58203.b6, 20081389.
26. Mitchell HS, Stephens E. Contraception choice for HIV positive women. Sex Transm Infect 2004, 80(3):167-173. 10.1136/sti.2003.008441, 1744846, 15169996.
27. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008, 13(2):123-132. 10.1080/13625180701829952, 18465473.
28. Womack J, Williams A. Hormonal contraception in HIV-Positive Women. AIDS Reader 2008, 18(7):372-376. 381.
29. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, HC, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010, 31(1):79-97. 10.1210/er.2009-0018, 2852204, 19903932.
30. Mingjia L, Short R. How oestrogen or progesterone might change a woman's susceptibility to HIV-1 infection. Aust N Z J Obstet Gynaecol 2002, 42(5):472-5. 10.1111/j.0004-8666.2002.00472.x, 12495087.
31. Baeten JM, Lavreys L, Overbaugh J. The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis 2007, 45(3):360-9. 10.1086/519432, 17599316.
32. Stringer EM, Levy J, Sinkala M, Chi BH, Matongo I, Chintu N, Stringer JS. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009, 23(11):1377-82. 10.1097/QAD.0b013e32832cbca8, 19448528.
33. Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis 2000, 182(3):708-15. 10.1086/315776, 10950763.
34. Smith SM, Mefford M, Sodora D, Klase Z, Singh M, Alexander N, Hess D, Marx PA. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS 2004, 18(12):1637-43. 10.1097/01.aids.0000131393.76221.cc, 15280774.
35. Stringer EM, Giganti M, Carter RJ, El-Sadr W, Abrams EJ, Stringer JS, . MTCT-Plus Initiative Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative. AIDS 2009, 23(Suppl 1):S69-77. 10.1097/01.aids.0000363779.65827.e0, 20081390, MTCT-Plus Initiative.
36. Polis CB, Wawer MJ, Kiwanuka N, Laeyendecker O, Kagaayi J, Lutalo T, Nalugoda F, Kigozi G, Serwadda D, Gray RH. Effect of hormonal contraceptive use on HIV progression in female HIV seroconverters in Rakai, Uganda. AIDS 2010, 24(12):1937-1944. 10.1097/QAD.0b013e32833b3282, 2939866, 20502314.
37. Richardson BA, Otieno PA, Mbori-Ngacha D, Overbaugh J, Farquhar C, John-Stewart GC. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS 2007, 21(6):749-753. 10.1097/QAD.0b013e328032790f, 17413696.
38. Chu JH, Gange SJ, Anastos K, Minkoff H, Cejtin H, Bacon M, Levine A, Greenblatt RM. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol 2005, 161(9):881-90. 10.1093/aje/kwi116, 15840621.
39. Kennedy M. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther 2008, 84(6):662-73. 10.1038/clpt.2008.202, 2684751, 18971926.
40. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokineticss in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005, 72(3):168-74. 10.1016/j.contraception.2005.03.005, 16102549.
41. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Frank Z, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010, 81(6):474-480. 10.1016/j.contraception.2010.01.016, 20472113.
42. Kuhnz W, Staks T, Jütting G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Contraception 1994, 50(6):563-79. 10.1016/0010-7824(94)90014-0, 7705098.
43. Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, Yu S, Lertora JJ, . ACTG A5093 Protocol Team Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007, 81(2):222-7. 10.1038/sj.clpt.6100040, 17192768, ACTG A5093 Protocol Team.
44. Watts DH, Jeong-Gun Park JG, Cohn SE, Yu S, Hitti J, Stek A, Pamela A, Clax PA, Muderspach L, Lertora JJ. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008, 77(2):84-90. 10.1016/j.contraception.2007.10.002, 2424313, 18226670.
45. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008, 90(4):965-71. 10.1016/j.fertnstert.2007.07.1348, 17880953.
46. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, Robinson P. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-Infected women. J Acquir Immune Defic Syndr 2002, 29(5):471-7.
47. Joshi AS, Fiske WD, Benedek IH, White SJ, Joseph JL, Kornhauser DM. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. Conf Retrovir Oppor Infect 1998, 5:abstract no. 348.
48. Sevinsky H, Eley T, He B, Persson A, Garner D, Yones C, Nettles R, Bertz R, Zhang J. Effect of efavirenz on the pharmacokinetics of ethinyl estradiol and norgestimate in healthy female subjects. 48th Annual ICAAC/IDSA 46th Annual Meeting, October 25-28 2008, Washington, DC.
49. Schöller-Gyürea M, Kakudab TN, Woodfalla B, Aharchia F, Peetersa M, Vandermeulena K, Hoetelmansa RM. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009, 80(1):44-52. 10.1016/j.contraception.2009.01.009, 19501215.
50. Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy 2009, 29(8):924-9. 10.1592/phco.29.8.924, 19637945.
51. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998, 46(2):111-6. 1873670, 9723818.
52. Sekar VJ, Lefebvre E, Guzman SS, Felicione E, De Pauw M, Vangeneugden T, Hoetelmans RM. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther 2008, 13(4):563-9.
53. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr 2010, 55(4):473-82. 10.1097/QAI.0b013e3181eb5ff5, 20842042.
54. Fröhlich M, Burhenne J, Martin-Facklam M, Weiss J, von Wolff M, Strowitzki T, Walter-Sack I, Haefeli WE. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004, 57(3):244-52. 10.1111/j.1365-2125.2003.01983.x, 1884449, 14998420.
55. Tackett D, Child M, Agarwala S, Geiger M, Geraldes M, Laura B, O'Mara E. Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects. Conf Retrovir Oppor Infect 2003, 10:abstract no. 543.
56. Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br J Clin Pharmacol 2008, 65(Suppl 1):19-26. 2311411, 18333862.
57. Merck Crixivan (indinavir), package insert. Merck., http://www.merck.com/product/usa/pi_circulars/c/crixivan/crixivan_pi.pdf
58. GlaxoSmithKline Agenerase (amprenavir), package insert. GlaxoSmithKline., http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=1873
59. Pharmaceuticals A. Viracept (nelfinavir) package insert. , http://us.gsk.com/products/assets/us_viracept.pdf
60. Becker KL. Principles and practice of endocrinology and metabolism. 2001, 1018. Philadelphia: Lippincott Williams and Wilkins.
61. Schindler AE. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol 2010, 62(4):319-29.
62. Womack JA, Scherzer R, Cole SR, Fennie K, Williams AB, Grey M, Minkoff H, Anastos K, Cohen MH, Tien PC. Hormonal contraception and metabolic outcomes in women with or at risk for HIV infection. J Acquir Immune Defic Syndr 2009, 52(5):581-7. 10.1097/QAI.0b013e3181b9e5ee, 2886798, 19950431.
63. Beksinska ME, Kleinschmidt I, Smit JA, Farley TM, Rees HV. Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception. Contraception 2009, 80(2):128-32. 10.1016/j.contraception.2009.02.001, 19631787.
64. DEPO-PROVERA® Contraceptive Injection, medroxyprogesterone acetate injectable suspension, USP. , http://www.drugs.com/pro/depo-provera.html
65. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, Stager M, Brown R, Bruner A, Coupey S, Hertweck P, Bone H, Wolter K, Nelson A, Marshall S, Bachrach LK. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010, 81(4):281-91. 10.1016/j.contraception.2009.11.003, 20227543.
66. Pongsatha S, Ekmahachai M, Chaovisitsaree S, Suntornlimsiri N, Morakote N. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study. J Med Assoc Thai 2009, 92(10):1263-7.
67. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrovandi GM, Cardoso SW, Santana JL, Brown TT. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010, 51(8):937-46. 10.1086/656412, 3105903, 20839968.
68. Beksinska ME, Smit JA, Ramkissoon A. Progestogen-only injectable hormonal contraceptive use should be considered in analysis of studies addressing the loss of bone mineral density in HIV-positive women. J Acquir Immune Defic Syndr 2010, 54(4):e5..
69. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001, 15(14):1823-9. 10.1097/00002030-200109280-00011, 11579244.
70. Hengcharoen S, Chaithongwongwatthana S. Awareness of Emergency Contraception in Adolescent Mothers. Thai J Obstet Gynecol 2009, 17:175-180.
71. Carten ML, Kiser J, Kwara A, MaWhinney S, Cu-Uvin S. Pharmacokinetic (PK) Interactions between the Hormonal Emergency Contraception Plan B®(Levonorgestrel) and Efavirenz (EFV). Conf Retrovir Oppor Infect 2010, 17:abstract no. 934.